Research programme: gene-activated interferon beta - Shire Pharmaceuticals

Drug Profile

Research programme: gene-activated interferon beta - Shire Pharmaceuticals

Alternative Names: GA-INFβ; Gene-activated interferon beta research programme - Shire Pharmaceuticals; Gene-activated β-Ifn; Research programme: gene-activated interferon beta - Transkaryotic Therapies

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Gene therapies; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
  • 19 Mar 2010 Gene-Activated interferon beta is available for licensing as of 19 Mar 2010. http://www.shire.com
  • 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top